CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

02 May 2024 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

09 Apr 2024 16:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

19 Mar 2024 16:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024

13 Mar 2024 16:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases

12 Feb 2024 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma

08 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

06 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell

23 Jan 2024 17:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial

09 Dec 2023 12:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

07 Nov 2023 16:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition

02 Nov 2023 09:15:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases

01 Nov 2023 19:31:53 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023

31 Oct 2023 16:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Confirms Planned Initiation of Soquelitinib (CPI-818) Phase 3 Registrational Clinical Trial in Peripheral T Cell Lymphoma Following Meeting with FDA

06 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results

08 Aug 2023 16:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter Financial Results on August 8, 2023

01 Aug 2023 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential Novel Approach to Immunotherapy Based on Inhibition of ITK with Soquelitinib (CPI-818)

06 Jul 2023 12:59:15 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New Ciforadenant Preclinical Data at the 2nd JCA-AACR Precision Cancer Medicine International Conference

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New CPI-818 Interim Data at the International Conference on Malignant Lymphoma

15 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the Jefferies Healthcare Conference

31 May 2023 08:30:00 By Nasdaq GlobeNewswire